Effects of metestrous administration of a norgestomet implant and injection of norgestomet and estradiol valerate on luteinizing hormone release and development and function of corpora lutea in suckled beef cows.
Sixteen suckled beef cows were used to determine effects of Syncro-Mate-B (SMB) on the development and function of corpora lutea (CL) and LH release. Twelve cows were treated 2 d after estrus with the standard SMB treatment regimen, a 6-mg Norgestomet ear implant (in situ 9 d) and a 2-mL i.m. injection of 3 mg of Norgestomet and 5 mg of estradiol valerate at time of implant insertion. Four cows served as untreated controls. In cows treated with SMB with subsequently nonfunctional CL (n = 5), mean concentrations of progesterone (P4) were lower on d 9, 12 (implant removal), and 14 of the treated cycle than in control cows or in those cows treated with SMB that developed functional CL (P < .01). In cows treated with SMB that developed functional CL (n = 7), mean concentrations of P4 were lower only on d 12 of the treated cycle than those in control cows (P < .01). In cows treated with SMB with subsequently nonfunctional CL, CL were smaller from d 9 through 14 of the treated cycle than in control cows or in those cows treated with SMB that developed functional CL (P < .01). In cows treated with SMB that developed functional CL, CL were smaller on d 9 and 11 of the treated cycle than in control cows (P < .01). Regardless of subsequent CL function, mean concentrations of LH and numbers of LH pulses were lower in cows treated with SMB than in control cows on d 3 and 4 of the treated cycle (P < .01).(ABSTRACT TRUNCATED AT 250 WORDS)
Burns
P D
PD
Animal, Dairy, and Veterinary Sciences Department, Clemson University, SC 29634-0361.
Spitzer
J C
JC
Bridges
W C
WC
Henricks
D M
DM
Plyler
B B
BB
D000818:Animals; D002417:Cattle / Q000502:physiology*; D003338:Corpus Luteum / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D004343:Drug Implants; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000494:pharmacology; D004973:Estrus Synchronization; D005260:Female; D007273:Injections, Intramuscular / Q000662:veterinary; D007774:Lactation / Q000502:physiology; D007986:Luteinizing Hormone / Q000378:metabolism; D008686:Metestrus / Q000187:drug effects* / Q000502:physiology; D011282:Pregnenediones / Q000008:administration & dosage / Q000494:pharmacology*; D011374:Progesterone / Q000097:blood; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000494:pharmacology*
D004343:Drug Implants; D004966:Estrogens, Conjugated (USP); D011282:Pregnenediones; D045167:Progesterone Congeners; C100284:norgestomet; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone